C
Contraria Biotech
Biotech & Life Sciences · Siena, Italy · Founded 2017
Develops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics MoreLess
Achilles Vaccines operates in the biopharmaceutical sector, focusing on the early-stage development of vaccines and immunotherapeutics. The company leverages a versatile technology platform that utilizes bacteria to produce self-adjuvanting vesicles capable of delivering antigenic molecules. Achilles Vaccines serves clients in the healthcare and pharmaceutical industries, addressing critical needs such as malaria, COVID-19, and bacterial infections. The company employs advanced laboratory and digital technologies, including the NGVR method, to rapidly identify effective vaccine targets. Its business model revolves around research and development, supported by significant seed financing and partnerships, such as the EU Malaria Fund. Revenue is generated through the development and commercialization of biopharmaceutical products, including vaccines and immunotherapeutics.
Keywords: biopharmaceutical, vaccines, immunotherapeutics, NGVR, bacterial infections, malaria, COVID-19, biotechnology, advanced technology, early-stage development.
Company overview
Contraria Biotech company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Siena, Italy
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 33.9
Valuation & funding
Contraria Biotech funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jun 2020 | $12M | $48M | European Investment Bank · Bill & Melinda Gates Foundation · Toscana Life Sciences · Fondazione Monte dei Paschi di Siena | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Contraria Biotech website traffic
Latest recorded traffic for Contraria Biotech is 220 monthly website visits, down 18.5% over the last three months. Contraria Biotech's team grew 0% over the past year.
Comparisons
Contraria Biotech compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Contraria Biotech's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Contraria Biotech's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Contraria Biotech has talent and traffic
In the news
Latest news about Contraria Biotech
Recent press, funding announcements, and product moves mentioning Contraria Biotech — open to read from the original sources.
Market sentiment
What the market is saying about Contraria Biotech
An AI-synthesized read of the highest-engagement posts about Contraria Biotech on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Contraria Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.